AstraZeneca Pharma India Limited Q4 FY25 results press release summary

Results press release of 30 May 2025, summarised by AI from the filing.

AstraZeneca Pharma India FY 2024-25 revenue ₹17162.9 Mn, up 32%, with Core EPS ₹46.30.

Key takeaways

1. FY25 revenue Total revenue from operations ₹17162.9 Mn, up 32% year-on-year.
2. Core EPS Core EPS announced as ₹46.30.
3. PAT decline Profit after exceptional item and tax ₹1157.4 Mn (FY 2023-24: ₹1615.1 Mn).
4. Oncology growth Oncology revenue ₹11171.4 Mn (FY 2023-24: ₹7510.9 Mn).
5. Approvals 14 approvals across portfolio since 2023, including multiple launches in FY 2024-25.

Original filing on BSE

AstraZeneca Pharma India Limited Q1 FY27 results

As filed: Revenue ₹683 cr (+30% year on year), EBITDA ₹48.9 cr (−40% year on year), PAT ₹37.9 cr (−32% year on year), EBITDA margin 7.2% (−842 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

• Q4 FY26: Revenue ₹579 cr (+21% year on year), EBITDA ₹60.9 cr (−30% year on year), PAT ₹44.9 cr (−23% year on year), EBITDA margin 10.5% (−760 bps). Score 40 of 100, Below trend. Revenue growth was well below the company's own trend; EBITDA and profit growth were below it. EBITDA margin fell 760 bps year on year. Revenue fell 5% from last quarter. Revenue rose ₹98.6 cr on a year ago, more than the ₹97.0 cr it added the year before. Share price after the results: −6.4% in 30 days (Nifty 500: +0.9%).
• Q3 FY26: Revenue ₹612 cr (+39% year on year), EBITDA ₹44.8 cr (−42% year on year), PAT ₹32.6 cr (+5% year on year), EBITDA margin 7.3% (−1,000 bps). Score 48 of 100, In line with trend. Revenue growth was above the company's own trend; EBITDA growth was below it; profit growth was in line with it. EBITDA margin fell 1000 bps year on year. Profit fell 40% from last quarter. Share price after the results: −7.4% in 30 days (Nifty 500: −10.1%).
• Q2 FY26: Revenue ₹559 cr (+37% year on year), EBITDA ₹76.0 cr (+46% year on year), PAT ₹54.0 cr (+42% year on year), EBITDA margin 13.6% (+85 bps). Score 65 of 100, Above trend. Revenue and profit growth were above the company's own trend; EBITDA growth was in line with it. EBITDA margin rose 85 bps year on year. Profit fell 4% from last quarter. Revenue rose ₹151 cr on a year ago, more than the ₹97.0 cr it added the year before. Share price after the results: +1.6% in 28 days (Nifty 500: +1.3%).
• Q1 FY26: Revenue ₹526 cr (+36% year on year), EBITDA ₹82.0 cr (+110% year on year), PAT ₹56.0 cr, EBITDA margin 15.6% (+554 bps). Score 69 of 100, Above trend. Revenue and EBITDA growth were above the company's own trend. EBITDA margin rose 554 bps year on year. Profit fell 3% from last quarter. Revenue rose ₹138 cr on a year ago, more than the ₹93.0 cr it added the year before. Share price after the results: +7.0% in 29 days (Nifty 500: +2.2%).
• Q4 FY25: Revenue ₹480 cr (+25% year on year), EBITDA ₹87.0 cr (+78% year on year), PAT ₹58.0 cr (+49% year on year), EBITDA margin 18.1% (+533 bps). Score 58 of 100, In line with trend. Revenue growth was below the company's own trend; EBITDA growth was in line with it; profit growth was above it. EBITDA margin rose 533 bps year on year. Revenue rose ₹97.0 cr on a year ago, against ₹98.0 cr the year before. Share price after the results: +11.7% in 28 days (Nifty 500: +3.6%).
• Q3 FY25: Revenue ₹440 cr (+44% year on year), EBITDA ₹77.0 cr (+300% year on year), PAT ₹31.0 cr (+280% year on year), EBITDA margin 17.5% (+1,000 bps). Score 98 of 100, Above trend. Revenue, EBITDA and profit before exceptional items growth were well above the company's own trend. EBITDA margin rose 1000 bps year on year.
• Q2 FY25: Revenue ₹408 cr (+31% year on year), EBITDA ₹52.0 cr (−4% year on year), PAT ₹38.0 cr (−27% year on year), EBITDA margin 12.8% (−462 bps). Score 40 of 100, In line with trend. EBITDA margin fell 462 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

AstraZeneca Pharma India Limited earnings call, investor presentation and press release summaries

• Q4 FY25: Results press release (30 May 2025)